The crucial role of RIG-I in upregulating neutrophil CXCR2 expression through the MAPK signaling pathway in viral pneumonia.

Publication date: Jun 18, 2026

Dysregulated neutrophilic inflammation is a hallmark of severe COVID-19, but the mechanisms driving human peripheral neutrophils (HPNs) recruitment remain incompletely defined. C-X-C motif chemokine receptor 2 (CXCR2), a key chemokine receptor on HPNs, is essential for HPNs recruitment during viral pneumonia. However, the role and underlying regulatory mechanisms of CXCR2 on HPNs during viral pneumonia remain unclear. We enrolled 66 COVID-19 patients (30 mild, 33 severe) and 31 healthy controls (HCs). The content of HPNs and the CXCR2 expression on the HPNs were tracked using flow cytometry, RT-qPCR, and ELISA. Transcriptomic sequencing identified differential pathways in the patients. In vitro, HPNs and lung epithelial cells (A549, BEAS-2B) were stimulated with the viral mimic poly(I: C) and treated with pathway inhibitors (CXCR2: SB225002; RIG-I: BX795; MEK: PD98059). In vivo, a poly(I: C)-induced acute lung injury mouse model was used to confirm the roles of RIG-I and CXCR2 in lung injury progression. Severe patients exhibited a higher HPN percentage and CXCR2 expression. Higher CXCR2 expression was correlated with poor prognosis and elevated inflammatory cytokines (TNF-α, IL-6, and IL-8). In vitro, poly(I: C) triggered lung epithelial cells to produce CXCR2 ligands (CXCL1/2/8), increase pro-inflammatory factors, and promote the HPNs migration to epithelial cells. However, CXCR2 antagonists could reduce the HPNs recruitment and inflammatory factors in HPNs supernatants. Mechanistically, poly(I: C)-mediated activation of intracellular RIG-I upregulated CXCR2 expression on HPNs via the MAPK pathway. In vivo, inhibiting CXCR2, RIG-I, or depleting neutrophils significantly alleviated poly(I: C)-induced inflammatory lung injury, inflammation, and neutrophil infiltration. Our study identifies the RIG-I-MAPK-CXCR2 axis as a novel pathogenic signaling cascade that drives dysregulated neutrophilic inflammation in COVID-19, providing a basis for novel therapeutic strategies against respiratory viral infections.

Open Access PDF

Concepts Keywords
Epithelial CXCR2
Pd98059 Human peripheral neutrophils
Pneumonia MAPK signaling pathway
Pro Viral pneumonia
Viral

Semantics

Type Source Name
pathway KEGG MAPK signaling pathway
disease MESH viral pneumonia
disease MESH inflammation
disease MESH COVID-19
disease MESH HPNs
disease MESH acute lung injury
disease MESH lung injury
disease MESH viral infections
drug DRUGBANK (S)-Des-Me-Ampa
pathway REACTOME Reproduction
disease MESH included
disease MESH Rheumatism
drug DRUGBANK Coenzyme M
drug DRUGBANK Tretinoin
disease MESH severe acute respiratory syndrome
disease MESH infections
disease MESH death
disease MESH influenza
disease MESH Acute respiratory distress syndrome
disease MESH chronic hepatitis
disease MESH dengue
drug DRUGBANK Oxygen
disease MESH pneumonia
disease MESH hepatic failure
disease MESH heart failure
disease MESH arrhythmia
drug DRUGBANK Medical air
drug DRUGBANK Methionine
disease MESH shock
disease MESH respiratory failure
drug DRUGBANK Edetic Acid
drug DRUGBANK Phosphate ion
disease MESH PBS
disease MESH APC
drug DRUGBANK Streptomycin
disease MESH FBS
drug DRUGBANK Formaldehyde
drug DRUGBANK Gentian violet cation
pathway REACTOME Apoptosis
drug DRUGBANK Propidium
drug DRUGBANK Iodide
pathway REACTOME Release
drug DRUGBANK Aspartame
drug DRUGBANK Sodium lauryl sulfate
disease MESH SDS
drug DRUGBANK Human Serum Albumin
disease MESH Rad
disease MESH body weight
disease MESH wet lung
drug DRUGBANK Proline

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *